天美传媒

Chair, Department of Urology and Director of Robotic Surgery, Roswell Park Cancer Institute Areas of expertise: Robotic surgery, bladder cancer, prostate cancer

As Professor of Medicine and Urology at Yale School of Medicine, Dr. Daniel P. Petrylak is a pioneer in the research and development of new drugs and treatments to fight prostate, bladder, kidney and testicular cancer. For patients fighting these types of cancers, Petrylak finds recent developments in the field of immunotherapy particularly promising. “Up until recently, bladder cancer had not seen any major advancement in more than 30 years,” he says. “Studies are ongoing, but interim results are exciting so far.” At the Smilow Cancer Hospital, Dr. Petrylak’s position as a national leader on clinical trials for men with prostate and bladder cancer has opened up a world of treatment options for patients in New England. “We offer the latest investigational drugs for these conditions, while providing the highest level of care,” he says. Dr. Petrylak received his MD from Case Western Reserve University School of Medicine and joined the Yale faculty in 2012. In addition to his role as professor, he is also a member of the Cancer Signaling Networks Research Program at Yale Cancer Center, which studies how cancer stem cells are regulated in the body and communicate with surrounding tissue. Roughly 40 physicians and scientists in the program work together to develop the best methods for matching patients with the appropriate cancer drugs. One of Dr. Petrylak’s key goals is to continue to successfully translate basic research into clinical practice. “One of the most significant accomplishments in my career was moving docetaxel (an antineoplastic agent) therapy for the most advanced form of prostate cancer from phase I to III,” he says. “We ran a trial which supported its approval for the most advanced form of prostate cancer.” Dr. Petrylak currently serves as either the principal investigator or co-principal investigator on seven Southwest Oncology Group (SWOG) clinical trials for genitourinary cancers. To date, he has authored more than 100 peer-reviewed articles on prostate and bladder cancer research.

Dr. Preston C. Sprenkle specializes in the treatment of urologic cancers, including prostate cancer, kidney cancer, bladder cancer, testicular cancer and sarcoma 鈥� a rare kind of cancer that grows in cells that connect or support other parts of the body, like bone or muscle.
Dr. Sprenkle has dedicated his career to using the latest imaging technologies to improve diagnosis. He was one of the first physicians nationwide to implement the use of the Artemis Device. This machine, introduced in 2009, allows a surgeon to use 3D ultrasound technology and merge it with even more precise magnetic resonance imaging (MRI) to accurately identify cancerous tumors.
鈥淪killed and experienced radiologists are rare for this relatively new technique,鈥� Dr. Sprenkle explains. 鈥淎t Yale, we are fortunate to have some of the world leaders in prostate MRI.鈥�
Dr. Sprenkle is also a pioneer in 鈥渇ocal therapy,鈥� which allows a surgeon to treat tiny prostate lesions, rather than the whole organ. This avoids many of the side effects鈥攕uch as erectile dysfunction and incontinence鈥攖hat may follow the removal of the whole prostate.
鈥淓xciting technological advances are revolutionizing urology. Prostate cancer is very common and current treatments can majorly impact a man's sexual and urinary function,鈥� Dr. Sprenkle says. 鈥淒eveloping ways to minimize the impact of prostate cancer diagnosis and treatment on a man's health and quality of life is tremendously rewarding.鈥�
Dr. Sprenkle believes in working with patients to come up with individualized treatment plans. 鈥淚 want my patients to feel that I hear their concerns and treat them like a person. I am pleased at the end of a long consultation when they feel like they understand their disease and their options.鈥�

Education & Training:
Non Degree Program-Yale School of Management, Emerging Leaders Program (2018)
Fellowship-Memorial Sloan Kettering Cancer Center (2011)
Residency-New York Presbyterian Hospital (2009)
Internship-New York Presbyterian Hospital (2005)
MD-Columbia University (2004)
BA-Stanford University, Human Biology (1998)

Dr. Kara L. Watts, Associate Professor of Urology, joined the urology faculty at Montefiore in 2016. She completed a fellowship in Quality and Performance Improvement in Healthcare and an extended observership in focal ablation for prostate cancer in the UK. She serves as the Director of Quality Assurance and Improvement for the Department of Urology and leads the prostate cancer screening program.
Dr. Watts' clinical practice focuses on BPH, endourology, and prostate cancer detection and ablation. She also offers image-guided focal ablation for localized prostate cancer. She has a particular interest in active surveillance of prostate cancer and incorporating imaging modalities, particularly MRI imaging, into the diagnosis and treatment of localized prostate cancer.
Dr. Watts has numerous peer-reviewed publications, written several book chapters and co-edited a textbook. She has presented both nationally and internationally at various conferences and with the AUA regarding her work on quality improvement in healthcare and active surveillance and focal ablation in prostate cancer. She is involved in several national and international committees and editorial boards, including the AUA Quality Improvement and Patient Safety Committee, the Prostate Cancer Active Surveillance Research Initiative Advisory Committee, and the Urology Times Editorial Board.

I am a surgeon who specializes in nerve-sparing  for the treatment of  and salvage radical prostatectomy in patients with prostate cancer in whom radiation therapy has failed.
I completed my fellowship in urologic oncology in 1995 and have been in practice since then, devoting the past 15 years exclusively to the care of men with prostate cancer.

---

As Professor of Medicine and Urology at Yale School of Medicine, Dr. Daniel P. Petrylak is a pioneer in the research and development of new drugs and treatments to fight prostate, bladder, kidney and testicular cancer. For patients fighting these types of cancers, Petrylak finds recent developments in the field of immunotherapy particularly promising. “Up until recently, bladder cancer had not seen any major advancement in more than 30 years,” he says. “Studies are ongoing, but interim results are exciting so far.”
At the Smilow Cancer Hospital, Dr. Petrylak’s position as a national leader on clinical trials for men with prostate and bladder cancer has opened up a world of treatment options for patients in New England. “We offer the latest investigational drugs for these conditions, while providing the highest level of care,” he says.
Dr. Petrylak received his MD from Case Western Reserve University School of Medicine and joined the Yale faculty in 2012. In addition to his role as professor, he is also a member of the Cancer Signaling Networks Research Program at Yale Cancer Center, which studies how cancer stem cells are regulated in the body and communicate with surrounding tissue. Roughly 40 physicians and scientists in the program work together to develop the best methods for matching patients with the appropriate cancer drugs.
One of Dr. Petrylak’s key goals is to continue to successfully translate basic research into clinical practice. “One of the most significant accomplishments in my career was moving docetaxel (an antineoplastic agent) therapy for the most advanced form of prostate cancer from phase I to III,” he says. “We ran a trial which supported its approval for the most advanced form of prostate cancer.”
Dr. Petrylak currently serves as either the principal investigator or co-principal investigator on seven Southwest Oncology Group (SWOG) clinical trials for genitourinary cancers. To date, he has authored more than 100 peer-reviewed articles on prostate and bladder cancer research.

Dr. Sarmad Sadeghi earned his medical degree at Tehran University of Medical Sciences. He has a Master of Science degree (MS) in Health Information Sciences and a Doctor of Philosophy degree (PhD) in Public Health Management and Policy Sciences from the University of Texas Health Sciences Center at Houston.
He completed his internal medicine residency at the University of Texas Medical School at Houston and the Cleveland Clinic Foundation. He completed his hematology/oncology fellowship at the Cleveland Clinic Taussig Cancer Institute. Dr. Sadeghi joined the faculty at the division of oncology of University of Southern California in 2013 and has a clinical and research focus in genitourinary malignancies, specifically bladder, kidney and prostate cancers.
Dr. Sadeghi is the study chair and principal investigator of a number of multicenter clinical trials and is also an active member of SWOG cooperative group and the California Cancer Consortium.
Dr. Sadeghi is well published with several original articles and abstracts in peer reviewed journals and international meetings.

Dr. Erminia Massarelli is a hematologist in Duarte, California and is affiliated with . She received her medical degree from University of Naples Faculty of Medicine and has been in practice for more than 20 years. Dr. Erminia Massarelli has expertise in treating lung cancer, breast cancer, prostate cancer, among other conditions - see all areas of . Dr. Erminia Massarelli accepts Medicare, Blue Cross, United Healthcare - see other .

, is a board-certified urologist who specializes in detecting, treating and preventing genitourinary cancer. He is experienced in surgical and nonsurgical treatments for all urologic malignancies, including adrenal, upper tract, renal, bladder, prostate, penile and testicular cancers. He also has expertise in minimally invasive approaches to urologic surgery.
As an associate professor in the Department of Urology, Bagrodia trains medical students, residents and fellows at University of California San Diego School of Medicine, where he leads the genitourinary disease team. He has focused his clinical and research interests on understanding molecular attributes of germ cell tumors, which cause testicular cancer, with the goal of ultimately improving treatments and clinical care. He also has been actively involved in understanding and overcoming societal and epidemiological barriers to optimal care in testicular cancer patients.
Bagrodia, , has been involved in clinical trials for patients with testicular cancer and has conducted extensive research in urologic oncology, primarily in biomarker profiles and molecular signatures of urologic tumors as predictors of clinical outcomes. He has been funded through intramural research grants and also via competitive grants from the Cancer Prevention and Research Institute of Texas (CPRIT) and the National Institutes of Health.
He is the principal author or co-author of more than 150 articles in peer-reviewed publications such as Journal of Clinical Oncology, Nature Genetics, European Urology, Journal of Urology, Urologic Oncology, and Urology. Dr. Bagrodia is also a reviewer for many of these publications, as well as for the British Journal of Urology, Journal of Clinical Pathology and the Annals of Surgical Oncology. He also has contributed to several textbooks.
He also speaks Hindi.

As a dedicated radiologist with a strong commitment to patient care, innovation, and education, I bring over 15 years of experience to Corewell Health at William Beaumont University Hospital Royal Oak, MI. 

Leadership and Operations:
In my multifaceted role as Medical Director of Corewell Health East Medical Group Radiology, I help lead and oversee operations at Royal Oak, Troy, and Grosse Pointe hospitals, working diligently to ensure the highest standards of patient care and operational excellence. My focus on efficiency and quality has been instrumental in enhancing the healthcare experience for our community.

Physician Recruitment:
As the lead physician recruiter for our high-quality employed group, I am deeply involved in shaping our team with top-tier talent. My dedication to assembling a team of exceptional healthcare professionals contributes significantly to our organization's continued success.

Research Scientist:
I am a research scientist with a specialized focus on prostate cancer MRI. My work in this field is driven by a passion for advancing diagnostic techniques and improving patient outcomes. I collaborate with esteemed researchers and institutions to push the boundaries of medical imaging in the fight against prostate cancer.

Education and Mentorship:
In addition to my clinical and research roles, I take pride in my role as an educator. I actively mentor and train radiology residents and fellows, imparting knowledge and fostering the growth of future leaders in the field. 

Connect with Me:
I am always eager to connect with fellow healthcare professionals, researchers, educators, and those who share a passion for the advancement of medical science and patient care.

William Russell, MD, specializes in radiation oncology at Ochsner MD Anderson Cancer Center in Baton Rouge, Louisiana. He has expertise in conformal treatment planning, prostate cancer and breast cancer
Dr. Russell earned a medical degree from the University of Mississippi School of Medicine. He completed a residency in radiation oncology from the University of North Carolina Hospitals in Chapel Hill, and a residency in internal medicine with the University of Mississippi. He is double-board certified in internal medicine and radiation oncology. He is a clinical assistant professor of medicine at Tulane School of Medicine. He served in the United States Army and Air Force for a total of 21 years, including 12 years of active duty.